Sub menu

 

 

Australian prescription medicine decision summaries

Search our decision summaries for the registration of new prescription medicines.

For more information, visit the About Australian prescription medicine decision summaries information page.

We have redesigned our prescription medicine decision summaries (AusPMDSs) to make it easier to understand how prescription medicines are registered in Australia. 

The redesigned AusPMDSs will offer clear, accessible information about recent medicine registration decisions.

Use the filters below to narrow your search.

Filter results

You can narrow down the results using the filters.

Published date

245 result(s) found, displaying 126 to 150

  • Xpovio

    Prescription medicine decision summary
    TGA decision: Xpovio (selinexor) is approved to treat multiple myeloma.

  • Evusheld

    Prescription medicine decision summary
    TGA decision: Evusheld (tixagevimab/cilgavimab) is approved for the treatment of pre-exposure prophylaxis of COVID-19.

  • Sogroya

    Prescription medicine decision summary
    TGA decision: Sogroya (somapacitan) is approved to treat adults with growth hormone deficiency (AGHD).

  • Jemperli

    Prescription medicine decision summary
    TGA decision: Jemperli (dostarlimab) is approved to treat patients with recurrent or advanced mismatch repair deficient endometrial cancer.

  • Rybelsus

    Prescription medicine decision summary
    TGA decision: Rybelsus (semaglutide) is approved to treat type 2 diabetes mellitus

  • Empaveli

    Prescription medicine decision summary
    TGA decision: Empaveli (pegcetacoplan) is approved to treat adult patients with paroxysmal nocturnal haemoglobinuria (PNH).

  • Tepmetko

    Prescription medicine decision summary
    TGA decision: Tepmetko (tepotinib) is approved to treat locally advanced or metastatic non-small cell lung cancer (NSCLC).

  • Vaxneuvance

    Prescription medicine decision summary
    Australian prescription medicine decision summary

  • Lagevrio

    Prescription medicine decision summary
    TGA decision: Lagevrio (molnupiravir) is approved for the treatment of adults with COVID-19.

  • Lutetium (177Lu) Chloride

    Prescription medicine decision summary
    ANSTO Lutetium (177Lu) chloride (lutetium (177 Lu) chloride) is approved to treat non resectable or metastatic neuroendocrine tumours.

  • Paxlovid

    Prescription medicine decision summary
    TGA decision: Paxlovid (nirmatrelvir/ritonavir) is approved for the treatment of adults with COVID-19.

  • Nuvaxovid

    Prescription medicine decision summary
    Australian prescription medicine decision summary

  • Koselugo

    Prescription medicine decision summary
    TGA decision: Koselugo (selumetinib) is approved to treat paediatric patients aged 2 years and above, with neurofibromatosis type 1 (NF1)

  • Ngenla

    Prescription medicine decision summary
    TGA decision: Ngenla (somatrogon) is approved to treat paediatric growth disturbance

  • Kerendia

    Prescription medicine decision summary
    Australian prescription medicine decision summary

  • Nextstellis

    Prescription medicine decision summary
    TGA decision: Nextstellis (estetrol monohydrate and drospirenone) is approved for use by women of reproductive potential to prevent pregnancy.

  • Regkirona

    Prescription medicine decision summary
    Australian prescription medicine decision summary

  • Nexviazyme

    Prescription medicine decision summary
    TGA decision: Nexviazyme (avalglucosidase alfa) is approved to treat Pompe disease (acid α-glucosidase deficiency)

  • Verquvo

    Prescription medicine decision summary
    TGA decision: Verquvo (vericiguat) is approved to treat symptomatic chronic heart failure

  • Rholistiq

    Prescription medicine decision summary
    TGA decision: Rholistiq (belumosudil mesilate) is approved to treat chronic graft-versus-host disease (GVHD)

  • Illuccix

    Prescription medicine decision summary
    TGA decision: Illuccix (Glu-urea-Lys(ahx)-hbed-CC) is a radioactive diagnostic agent used to assist in the treatment of prostate cancer.

  • Truseltiq

    Prescription medicine decision summary
    TGA decision: Truseltiq (infigratinib) is approved to treat cholangiocarcinoma.

  • Bevacip/Bevaciptin

    Prescription medicine decision summary
    TGA decision: Bevacip/Bevaciptin (bevacizumab) is approved to treat various types of cancers.

  • VeraSeal

    Prescription medicine decision summary
    TGA decision: VeraSeal (human fibrinogen/ human thrombin) is approved to treat hemostasis.

  • Brukinsa

    Prescription medicine decision summary
    Australian prescription medicine decision summary